Form 4: MariMed Inc. Director Eva Selhub Acquires RSUs

MariMed Inc. Director Eva Selhub acquired 75,000 Restricted Stock Units (RSUs) on June 4, 2026, as part of the company's non-employee director compensation program.

Summary

• Eva Selhub, a Director at MariMed Inc., was granted 75,000 Restricted Stock Units (RSUs) on June 4, 2026.
• These RSUs are part of the company's compensation program for non-employee directors.
• The RSUs convert to common stock on a one-for-one basis.
• The RSUs will vest in full one year from the grant date, on June 4, 2027.
• Following this transaction, Eva Selhub beneficially owns 482,671 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard director compensation grant rather than a significant strategic or financial development.

Positives

• Director equity grant indicates alignment with company performance and long-term value.
• The grant of 75,000 RSUs shows continued investment and commitment from a key board member.
• Vesting schedule promotes retention and long-term focus for the director.

Future Outlook

The RSUs are set to vest in full one year from the grant date, indicating a future potential increase in directly held common stock for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the cannabis industry, aligning board incentives with shareholder interests and company growth.

Stakeholder Impact

• Shareholders: The grant aligns director interests with long-term shareholder value, but does not immediately impact share count or price.
• Employees: This is a standard director compensation practice and has no direct impact on employees.
• Management: Reinforces standard compensation practices for the board.

Next Steps

• Vesting of 75,000 RSUs on June 4, 2027.

Key Dates

Keywords

MariMed Inc., MRMD, Form 4, SEC Filing, Director Compensation, Restricted Stock Units, Equity Grant, Beneficial Ownership